Physician profile
Mark P Batrice
NPI 1164478038
$2,708.54
in general payments reported to CMS, 2019-2025
18 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $34.38 · 2021: $536 · 2022: $578 · 2023: $412 · 2024: $304 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.60 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $925.78 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $645.84 | 2021-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $250.08 | 2023-2025 | |
| Astellas Pharma US INC | $198.00 | 2019 | |
| Abbott Laboratories | $162.98 | 2021-2024 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $162.05 | 2019-2025 | Camzyos |
| Lilly USA, LLC | $77.74 | 2022-2023 | Mounjaro |
| Pfizer INC. | $70.80 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.29 | 2022-2025 | Jardiance |
| Allergan, INC. | $31.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.26 | 2024 | Airsupra |
| Dexcom, INC. | $18.13 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $16.42 | 2024 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $13.88 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $13.83 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Batrice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.